Home | News | News Archive | 2009 & before | PM Group signs €250m contracts in Asia

News Search

PM Group signs €250m contracts in Asia

PM Group has been awarded three major contracts with a gross capital value of some €250 million in Singapore, China and India.

The announcement was made during the recent Interphex Asia exhibition in Singapore where 10 Irish companies were represented at the Enterprise Ireland pavilion. Interphex Asia is the premier showcase for the Pharmaceutical service sector in the region and the strong presence by Irish companies demonstrates the increasing opportunities in Asian markets for Irish pharmaceutical service companies.

Making the announcement, PM Group outlined details of the three projects - the first is the project management, design and construction for a new secondary pharmaceutical technology centre at Singapore's Nanyang Polytechnic. This will enhance the polytechnic's facilities in providing educational services in science and technology. The second is project management for a confidential multi-national client on a new R&D campus in China (awarded together with M+W Zander), and the third is to develop Intas Biopharmaceuticals new large scale monoclonal antibody facility in Ahmedabad, India.

Speaking at the announcement, Allan Schouten, Managing Director PM Group Asia said 'We are very proud to have been entrusted with these three exciting new projects. This underlines PM Group's growing strength in Asia. With our Asian headquarters based in Singapore, we are well positioned to service the region, providing world-class project and construction management. The Nanyang Polytechnic and Intas Biopharmaceuticals projects are currently in design and construction is expected to commence later in 2009.”

Welcoming the announcement, Alan Dixon, Enterprise Ireland's Director for Asia Pacific, said “More Irish companies are setting up in Singapore, using it as a springboard for the Asia Pacific region, in particular reaching out to China and India. Currently, there are over 50 Irish companies in Singapore, many of which are within or supporting the pharmaceutical industry. The number of Singapore-based Irish companies has more than doubled over the past five years, and correspondingly the value of their business has increased significantly. Ireland's rich experience in the pharmaceutical industry has allowed its companies to provide strong support to Asia's pharmaceutical industry. Many of the Irish companies exhibiting at Interphex are service providers, strengthening Singapore and Asia's pharmaceutical capabilities, training manpower and facilitating operations.”

The Interphex Asia trade fair was also the occasion for a site visit to Wyeth Nutrition by H.E. Dr Richard O'Brien, Ireland's Ambassador to Singapore, to witness the completion of the 12,000sqm extension of Wyeth's facility in Tuas, Singapore which was project managed by PM Group.